Stock BCAB BIOATLA, INC.
Add to a list
To use this feature you must be a member
Log inSign up

All News BioAtla, Inc.

Equities

BCAB

US09077B1044

Market Closed - Nasdaq
Other stock markets
 16:00:00 2024-04-26 EDT 		5-day change 1st Jan Change
2.54 USD +12.89% Intraday chart for BioAtla, Inc. +20.67% +3.25%
03-27 HC Wainwright Adjusts BioAtla's Price Target to $7 From $10, Maintains Buy Rating MT
03-26 Transcript : BioAtla, Inc., Q4 2023 Earnings Call, Mar 26, 2024

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
BioAtla Announces Upcoming Poster Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
AQ
HC Wainwright Adjusts BioAtla's Price Target to $7 From $10, Maintains Buy Rating
MT
Transcript : BioAtla, Inc., Q4 2023 Earnings Call, Mar 26, 2024
BioAtla Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Progress
AQ
BioAtla, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023
CI
BioAtla to Announce Fourth Quarter and Full-Year 2023 Financial Results and Provide Business Highlights on March 26, 2024
AQ
BioAtla Announces Poster Presentations at the 2024 American Association for Cancer Research (AACR) Annual Meeting
AQ
Transcript : BioAtla, Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-11-2024 09:45 AM
Sector Update: Health Care Stocks Rise in Late Afternoon Trading
MT
Sector Update: Health Care Stocks Advance in Afternoon Trading
MT
BioAtla Rallies After CEO Buys 50,000 Shares
MT
BioAtla to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
GL
Transcript : BioAtla, Inc. - Special Call
BioAtla, Inc.(NasdaqGM:BCAB) dropped from NASDAQ Biotechnology Index
CI
BioAtla Hosting Virtual R&D Day to Highlight BA3071 CAB-CTLA-4 Phase 1 Data in Multiple Solid Tumor Types
AQ
Bioatla Hosting Virtual R&D Day to Highlight Ba3071 Cab-Ctla-4 Phase 1 Data in Multiple Solid Tumor Types
CI
Transcript : BioAtla, Inc. - Special Call
BioAtla to Host Virtual R&D Day to Review BA3071 CAB-CTLA-4 Phase 1 Data in Multiple Solid Tumor Types on Wednesday, December 13, 2023
AQ
Sector Update: Health Care Stocks Slipping Tuesday Afternoon
MT
BioAtla Says Clinical Benefits, Safety Profile Support Further Evaluation of Potential Lung Cancer Therapy
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. BCAB Stock
  4. News BioAtla, Inc.